Outlook Eyes Blockbuster-Sized Sales For An Old Eye Drug In Wet-AMD
The company is seeking FDA approval for a first-time ophthalmic formulation of bevacizumab and also refiled its BLA.
You may also be interested in...
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.
Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.